Einträge von Topp, Max S auf dem Publikationsserver

Bethge, Wolfgang Andreas , Martus, Peter, Schmitt, Michael, Holtick, Udo, Subklewe, Marion, von Tresckow, Bastian , Ayuk, Francis, Wagner-Drouet, Eva Maria, Wulf, Gerald G, Marks, Reinhard, Penack, Olaf, Schnetzke, Ulf, Koenecke, Christian , von Bonin, Malte , Stelljes, Matthias, Glass, Bertram, Baldus, Claudia D, Vucinic, Vladan , Mougiakakos, Dimitrios, Topp, Max S, Fante, Matthias Alexander, Schroers, Roland, Bayir, Lale May, Borchmann, Peter, Buecklein, Veit, Hanoun, Christine, Thomas, Simone, Beelen, Dietrich W., Lengerke, Claudia, Kroeger, Nicolaus, Dreger, Peter und make_name_string expected hash reference (2022) GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. Volltext nicht vorhanden.

Behringer, Karolin, Goergen, Helen, Hitz, Felicitas, Zijlstra, Josée M, Greil, Richard , Markova, Jana, Sasse, Stephanie, Fuchs, Michael, Topp, Max S, Soekler, Martin, Mathas, Stephan, Meissner, Julia, Wilhelm, Martin, Koch, Peter, Lindemann, Hans-Walter, Schalk, Enrico, Semrau, Robert, Kriz, Jan, Vieler, Tom, Bentz, Martin, Lange, Elisabeth, Mahlberg, Rolf, Hassler, Andre, Vogelhuber, Martin, Hahn, Dennis, Mezger, Jörg, Krause, Stefan W , Skoetz, Nicole, Böll, Boris, von Tresckow, Bastian, Diehl, Volker, Hallek, Michael, Borchmann, Peter, Stein, Harald, Eich, Hans und Engert, Andreas (2015) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. The Lancet 385 (9976), S. 1418-1427. Volltext nicht vorhanden.

Knop, Stefan, Langer, Christian, Engelhardt, Monika, Muegge, Lars O, Reichle, Albrecht, Röllig, Christoph, Gramatzki, Martin, Roesler, Wolf, Topp, Max S, Wesemeier, Carmen, Hertenstein, Bernd, Sturm, Isrid, Dechow, Tobias, Kortüm, Martin, Sauerwein, Marianne, Einsele, Hermann und Bargou, Ralf (2010) The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma – First Results of a Phase II Trial by the German DSMM Group. Blood 116 (21), S. 1945. Volltext nicht vorhanden.